Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 55Myelodysplastic Syndromes 19Recurrence 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia, Myelomonocytic, Chronic 12Lymphoma, Non-Hodgkin 11Leukemia 11Multiple Myeloma 9Lymphoma, Mantle-Cell 7Hematologic Neoplasms 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Follicular 6Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myeloid 3Burkitt Lymphoma 3Neoplasms 2Neoplasm, Residual 2Myeloproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Biphenotypic, Acute 2Immunoglobulin Light-chain Amyloidosis 2Dendritic Cell Sarcoma, Interdigitating 2Waldenstrom Macroglobulinemia 1Thrombocytosis 1Thrombocythemia, Essential 1

Interventions

venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × GATA2 Deficiency × venetoclax × Clear all
NCT05211570 2025-10-02

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

AB Science

Phase 1/2 Recruiting
78 enrolled
Other hematologic neoplasm

GATA2 Deficiency, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡